Approved indications

- Dalbavancin is FDA-approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI), including cellulitis, major abscesses, and wound infections, caused by susceptible Gram-positive organisms such as Staphylococcus aureus (including many MRSA strains) and Streptococcus species in adults and children 3 months and older.

Off-label uses

- Clinicians sometimes use dalbavancin off-label for difficult Gram-positive infections such as osteomyelitis, certain bloodstream infections, or endocarditis when long-acting IV therapy is helpful; evidence is based on small trials, observational studies, and case series rather than large randomized registration trials.

Efficacy expectations

- Many patients begin to notice improvement in skin symptoms (less pain, redness, swelling) within 48–72 hours as the infection is brought under control.
- Clinical trials show dalbavancin is generally noninferior in cure rates to standard multi-day IV or IV-to-oral regimens for ABSSSI when caused by susceptible organisms.
- Compared with other IV antibiotics, its main advantage is similar efficacy with one or two infusions, which can reduce hospital stays and the need for long-term IV access.

Typical dosing and administration

- Adults with normal kidney function usually receive either a single 1500 mg IV infusion or a 2-dose regimen of 1000 mg IV on day 1 followed by 500 mg IV on day 8, infused over at least 30 minutes.
- Pediatric dosing (3 months and older) is weight-based, given as one or two IV infusions according to the prescribing information and clinical judgment.
- Dalbavancin is given only by intravenous infusion in a clinic, infusion center, or hospital; it is not taken by mouth and does not depend on food or time of day.

Special dosing instructions

- Dose adjustment is recommended for adults with significantly reduced kidney function who are not on regular hemodialysis; dosing in dialysis patients follows specific guidance from the prescriber.
- Infusion should be administered through an appropriate IV line, with the solution diluted and prepared according to the manufacturer’s instructions to reduce infusion reactions.

Missed dose and overdose

- If a scheduled second infusion (for the 2-dose regimen) is missed, patients should contact their healthcare provider as soon as possible to reschedule; do not try to “double up” doses on your own.
- Overdose is uncommon because dalbavancin is administered by healthcare professionals; if an excessive dose is suspected, clinicians provide supportive care and monitor kidney and liver function, as there is no specific antidote.

Common side effects

- Common reactions include nausea, headache, diarrhea, rash, and infusion-related reactions such as flushing or itching; these are usually mild to moderate and often start during or within a day or two of the infusion.
- Elevated liver enzymes can occur on blood tests, usually without symptoms, and are generally reversible.

Serious or rare adverse effects

- Serious allergic reactions (anaphylaxis, severe rash, difficulty breathing, swelling of the face or throat) are rare but require immediate emergency care.
- Severe skin reactions or significant liver injury (e.g., jaundice, dark urine, severe fatigue, right upper abdominal pain) are uncommon but must be reported promptly.
- Because dalbavancin is long-acting, adverse effects may persist or need monitoring for some time after the infusion.

Warnings and precautions

- Use with caution in patients with known hypersensitivity to glycopeptide antibiotics (such as vancomycin), as cross-reactivity can occur.
- In moderate to severe kidney impairment (and especially in patients not on regular hemodialysis), dose adjustment is recommended; liver impairment warrants closer monitoring though specific dose changes may not always be required.
- Data in pregnancy are limited; use is generally reserved for situations where the expected benefit outweighs potential risk. For breastfeeding, minimal information is available, so clinicians weigh the need for treatment against the unknown risk to the infant.
- Dalbavancin is approved for adults and pediatric patients 3 months and older; safety and efficacy are not established in younger infants.

Safety compared with other antibiotics

- Overall, dalbavancin is considered to have a safety profile similar to other IV glycopeptides but with less frequent dosing; it does not typically cause significant kidney toxicity at labeled doses, though renal function monitoring is still prudent in at-risk patients.

Side-effect reporting and safety updates

- Side effects should be reported to the prescribing clinician and can also be reported directly to the FDA’s MedWatch program or equivalent national pharmacovigilance systems.
- Updated safety information is published in the medication’s prescribing information and on regulatory agency websites.

Drug and other interactions

- Dalbavancin is not a strong inducer or inhibitor of major liver enzymes and has relatively few known drug–drug interactions compared with many other antibiotics.
- Clinically significant interactions with common prescription drugs, OTC medicines, supplements, or foods are uncommon, but all medications and herbal products should still be reviewed by the prescriber.
- Alcohol does not have a specific known interaction with dalbavancin, but limiting alcohol is sensible during treatment, especially to reduce liver stress.

Precautions and conditions requiring caution

- History of allergy or severe reaction to dalbavancin, vancomycin, or related glycopeptide antibiotics is a major precaution, and alternative therapy is often chosen.
- Patients with moderate to severe kidney impairment or unstable kidney function need dose adjustments or closer monitoring.
- Significant liver disease warrants careful clinical and laboratory monitoring because dalbavancin is partly eliminated through the liver and can affect liver enzymes.

Monitoring needs

- Depending on the patient’s health status, clinicians may monitor kidney function (serum creatinine), liver enzymes, and for signs of infusion reactions or allergic responses during and after infusion.
- Routine ECG monitoring is not typically required solely for dalbavancin, as it is not strongly associated with QT prolongation, but may be performed based on overall clinical context and co-medications.

Q: What is dalbavancin used for?
A: Dalbavancin is used to treat acute bacterial skin and skin structure infections caused by certain Gram-positive bacteria, including many strains of MRSA, in adults and children 3 months and older.

Q: How is dalbavancin given?
A: It is given as an intravenous infusion in a clinic, infusion center, or hospital, usually as a single dose or a two-dose regimen given one week apart.

Q: How quickly will I feel better after receiving dalbavancin?
A: Many people start to notice improvement in pain, redness, and swelling within 2 to 3 days, though full recovery may take longer depending on the severity of the infection.

Q: Can I take other medicines while on dalbavancin?
A: Dalbavancin has relatively few known drug interactions, but you should always tell your healthcare provider about all prescription drugs, OTC medicines, and supplements you use so they can check for any concerns.

Q: Is dalbavancin safe during pregnancy or breastfeeding?
A: Information in pregnancy and breastfeeding is limited, so the drug is usually used only when clearly needed; your healthcare provider will weigh the benefits of treatment against potential risks for you and your baby.

Storage

- Vials of dalbavancin powder are usually stored by healthcare providers at controlled room temperature, protected from light, and reconstituted/diluted just before use according to the package instructions.
- Once mixed for infusion, the solution should be used within the time limits specified by the manufacturer and kept under recommended temperature conditions until administration.

Disposal

- Unused or expired vials and leftover infusion solution should be discarded by healthcare professionals following local regulations for medical and pharmaceutical waste.
- Patients typically do not handle storage or disposal directly because dalbavancin is given in a clinic, infusion center, or hospital setting.